bioRxivImmunology
TGF--dependent Lymphoid Tissue Residency of Stem-like T cells Limits the Response to Tumor Vaccine
G. Li, L. Wang, C. Ma, W. Liao, Y. Liu, S. Mishra, X. Zhang, Y. Qiu, Q. Lu, N. Zhang
Abstract
Stem-like CD8+ T cells represent the key subset responding to multiple tumor immunotherapies, including tumor vaccination. However, the signals that control the differentiation of stem-like T cells are not entirely known. Most previous investigations on stem-like T cells are focused on tumor infiltrating T cells (TIL). The behavior of stem-like T cells in other tissues remains to be elucidated. Tissue-resident memory T cells (TRM) are often defined as a non-circulating T cell population residing in non-lymphoid tissues. TILs carrying TRM features are associated with better tumor control. Here, we found that stem-like CD8+ T cells differentiated into TRMs in a TGF-{beta} and tumor antigen dependent manner almost exclusively in tumor draining lymph node (TDLN). TDLN-resident stemlike T cells were negatively associated with the response to tumor vaccine. In other words, after tumor vaccine, TDLN stem-like T cells transiently lost TRM features, differentiated into migratory effectors and exerted tumor control.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response
K. A. Connolly, M. Kuchroo, … N. S. Joshi·bioRxiv·Jan 27, 2021
- Lymphatic egress recycles tumor-experienced effector CD8 T cells to sustain immune surveillance
Ines Delclaux, Katherine S. Ventre, … Amanda W. Lund·bioRxiv·May 5, 2026
- Stem-like PD-1+TCF-1+ CD8+ T cells result from helpless priming and rely on CD4+ T-cell help to complete their cytotoxic effector differentiation
Julia Busselaar, Douwe M. T. Bosma, … Jannie G. Borst·Journal for ImmunoTherapy of CancerPeer-reviewed·Apr 1, 2026
- PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells
Jyh Liang Hor, Edward C. Schrom, … Ronald N. Germain·NaturePeer-reviewed·Nov 26, 2025
- Resident memory T cell precursors in tumor draining lymph nodes require type-1 IFN for optimal differentiation
N. Khatwani, T. Searles, … M. J. Turk·bioRxiv·Aug 2, 2023
- Pre-existing intratumoral CD8 T cells substantially contribute to control tumors following therapeutic anti-CD40 and polyI:C based vaccination
A. Stevens, T. N. Bullock·bioRxiv·Aug 31, 2020